A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
about
New treatment options against gram-negative organismsFuture challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSASystemic antibiotics for treating diabetic foot infectionsInterventions for cellulitis and erysipelasTherapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaNewer antibacterial drugs for a new century.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Antibiotic discovery in the twenty-first century: current trends and future perspectives.Antibiotics and bacterial resistance in the 21st century.Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Antibiotic options for treating community-acquired MRSA.Linezolid for the treatment of drug-resistant infections.Current and novel antibiotics against resistant Gram-positive bacteriaEmerging agents to combat complicated and resistant infections: focus on ceftobiproleCeftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Quercetin 3-O-rutinoside mediated inhibition of PBP2a: computational and experimental evidence to its anti-MRSA activity.Epidemiology of Methicillin-Resistant Staphylococcus aureus Diabetic Foot Infections in a Large Academic Hospital: Implications for Antimicrobial StewardshipGenotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.The evaluation and treatment of complicated skin and skin structure infections.Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infectionsCeftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureusSoft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysisPharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsCurrent challenges in treating MRSA: what are the options?Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unitCeftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Newer developments in the treatment of Gram-positive infections.Diagnosis and management of community-associated MRSA infections in children.Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.New β-lactam antibiotics and β-lactamase inhibitors.
P2860
Q21194906-8119CE12-9C90-43FF-99D4-9A71213AF561Q22305769-88CCB9E0-7A97-4D34-9A5C-68F6EE94EB27Q24187313-217C3F9B-C8CB-43E9-AE34-DBFBAD345E2DQ24234864-72AE0CC4-D3E4-42E0-BD00-66ADC38290ADQ28080607-82CA7DC0-F635-4BBF-9539-8505697A2EBAQ29616084-714386C8-9DA7-4576-BE6F-048E3B83E147Q30433333-5DB71BFC-E70A-44E1-AD34-C7290D9C522FQ33429168-84963274-E3D5-4AE8-8764-ACBD7648CF1FQ34121033-46B2CAD8-7C90-4D98-AEE4-F98A9006D3FCQ34156349-9B5CD370-BC9D-46FB-920C-CDE8D446A1E9Q34187667-09D15093-1E94-46AC-81A5-264F42C8CD27Q34417616-8A97137E-6B85-4274-8995-A715BB8A9D1EQ34478074-D4EE671F-5C42-4C7E-9590-4F9064D76DE5Q34593646-87DF60F8-233D-4EA7-B2F7-08781DA5C627Q34894133-072ED2FD-869E-4A75-886A-0EE85631199FQ35026521-AAD34FF7-AF73-4CC7-808D-B776630045DBQ35026567-90435779-B0C8-4EF0-886C-26D3472BFB01Q35117981-08E28B1A-43B5-450B-932D-DF4B060A4FAAQ35305213-D48F214C-9D53-4319-A12D-AF379BCD4D5CQ36111450-018A2C09-1200-4380-A7B9-FB0D0B322DE8Q36489501-CBD84D79-54EF-440A-800E-8522E497FAA8Q36592698-17578027-AE6D-4E37-B091-F3F0DFF67037Q36686882-A50F86BF-31B5-4029-8847-3034B9A8678DQ37111836-4F7DEC29-C845-4DB4-B00D-28E3315F0A1BQ37115687-F8C8138F-A8BE-4BCD-A5F3-80F239D25101Q37162872-1A80AC59-5783-4B4D-B039-C3BB991C262FQ37204106-B03A2CE6-2598-42FA-A591-E47718B774B7Q37247602-E5423DA4-411E-46B7-8BF8-8D83ECC27FCFQ37274751-C6F01F09-E232-4864-B0D0-6AC37F5D4029Q37291338-786D5D5E-FD1D-4477-A550-FF8DCA1F4A2EQ37392891-E6E2F3E3-8102-4403-983B-0093CF680630Q37443022-F6383177-6E38-413D-A709-24B5430DB4E7Q37461413-7EA77A30-AE64-4045-9CBC-40E4548D6863Q37519733-40BC6182-D936-4D87-9C44-8809E1693CFEQ37593094-C559A561-0380-44B4-BBC1-7F520A271DFAQ37636151-052FE059-DD2C-40B2-91B0-D35D7C230EE5Q37682916-22C87D44-3EF8-4243-A350-E211291D2AB8Q37752231-D0AD1D9A-3240-4D7E-93C1-F421284ABDF5Q37785546-226D54AB-3858-49F2-8DBA-E4C9BB3D75B4Q37788685-4B07A560-039D-4D9F-ABF3-A64ABF1214FD
P2860
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A randomized, double-blind tri ...... and skin-structure infections.
@en
A randomized, double-blind tri ...... and skin-structure infections.
@nl
type
label
A randomized, double-blind tri ...... and skin-structure infections.
@en
A randomized, double-blind tri ...... and skin-structure infections.
@nl
prefLabel
A randomized, double-blind tri ...... and skin-structure infections.
@en
A randomized, double-blind tri ...... and skin-structure infections.
@nl
P2093
P356
P1476
A randomized, double-blind tri ...... and skin-structure infections.
@en
P2093
Gary J Noel
Juliana Ianus
Karen Bush
Partha Bagchi
Richard S Strauss
P304
P356
10.1086/526527
P407
P577
2008-03-01T00:00:00Z